Tony Keating says the study reveals many issues in the quality of cough recordings, and is not what the company expected.

ResApp crashes on study results

Shares in medical tech company ResApp Health plummeted 77 per cent today on disappointing results of a clinical study on its ResAppDx technology.


(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 28/02/18

1 year TSR5 year TSR
624thDepartment 13 International-32%-15%
625thEphraim Resources-32%-15%
761stResApp Health-60%85%
711 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

$65k Bought
$49k Bought
$49k Other
Total value as at the date of the transaction
Source: Morningstar


143rd-MOKO Social Media$1.2m
144th↑ResApp Health$1.1m
145th↑Department 13 International$1.1m
146th↑Ephraim Resources$1.1m
236 listed industrial companies ranked by revenue.
Source: Morningstar

Remuneration from ResApp Health

211thTony Keating$537k
1110thBrian Leedman$78k
365thRoger Aston$72k
Ranked by total remuneration from all listed WA companies

BNiQ Disclaimer